NCT06085482View on ClinicalTrials.gov

A Phase I Study of LY3502970 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

January 5, 2024

Study Completion Date

January 5, 2024

Conditions
Healthy
Interventions
DRUG

LY3502970

Administered orally

DRUG

[14C]-LY3502970

Administered IV

Trial Locations (1)

53704

Covance Clinical Research Inc, Madison

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06085482 - A Phase I Study of LY3502970 in Healthy Participants | Biotech Hunter | Biotech Hunter